Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.
Taking Ozempic for weight loss? You might find other benefits, too - and a few risks
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.
Landmark Study Reveals New Benefits and Risks of Obesity Drugs Like Ozempic
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.
Study ties Ozempic-like drugs to dozens of benefits and risks
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to increase the risk of many others.
Ozempic can help other chronic health conditions: Study | Morning in America
According to a Nature Medicine study, weight loss drugs can be highly effective in improving several unexpected health conditions. Dr. Anthony Harris discusses why he believes the FDA should update the drug's label to include other conditions it can treat.
Massive new study finds drugs like Ozempic affect 175 conditions — including a few surprises
A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — and even some new potential upsides. Analyzing the medical records of roughly 2.
Ozempic can lower chances of multiple health conditions but comes with risks, study finds
Ozempic, Wegovy, Zepbound and other drugs often used for weight loss can help lower the risk of a wide range of health conditions, according to a new study. But the drugs also pose certain risks. Kyle Benning explains.
A New Study Explored the Pros and Cons of Drugs Like Ozempic
GLP-1 drugs like Ozempic and Wegovy were initially used — and still are used — to treat diabetes. But in recent years, the uses of this class of drugs have grown in number. Nowadays, Ozempic and its ilk are often used for weight loss — and have shown promise in addressing other health issues.
phillyvoice.com5h
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
India Today on MSN8d
How Ozempic, Zepbound, and Mounjaro will transform India's weight loss market
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...
Ozempic May Damage Vital Organs, Study Finds
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
How Dolores Catania, 54, Lost 20 Pounds With Ozempic, Diet, And Exercise
Dolores was one of the first Real Housewives stars to open up about using weight-loss drugs. In 2023, she told The Sun that ...
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro
Anti-obesity medication: these are the surprising effects of taking Ozempic and Mounjaro - When Henry Conway hit his forties ...
The Ozempic debate: Large study reveals the good and the bad
A new study shows that GLP-1 drugs offer health benefits such as reducing risks for heart disease but also carry potential ...
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...